Evicenter
MarkdownMedical informationP&T meetings
Lonimecgene renparvovec (TSHA-102)

Rett syndrome

Launch
Not announced
Last updated
199 sources

Executive summary

Budget impact of Lonimecgene renparvovec

3 evidence topics · 19 sources

Summary

No published economic model, cost-effectiveness analysis, budget impact analysis, or health technology assessment of lonimecgene renparvovec (TSHA-102) was identified, and no price or pricing guidance has been announced. Taysha Gene Therapies has generated no revenue from commercial product sales, and access to TSHA-102 is currently limited to clinical trial participation, with no expanded access offered.

Taysha's annual report estimates an addressable population of 15,000 to 20,000 patients with typical Rett syndrome caused by a pathogenic or likely pathogenic MECP2 mutation in the United States, the European Union, and the United Kingdom, including 6,000 to 9,000 patients in the United States based on claims data and epidemiology data; the same report states that incidence and prevalence estimates rest on inexact assumptions and that the methodology is forward-looking and speculative. The third quarter 2026 results announcement repeats the 15,000 to 20,000 estimate.

Taysha's commercial preparations, as described in its own disclosures, include a commercial manufacturing and supply agreement with Catalent at an FDA-licensed gene therapy facility in Harmans, Maryland; a completed process performance qualification campaign for the commercial manufacturing process; $50.0 million in gross proceeds from its at-the-market equity offering, with proceeds intended to support a potential commercial inventory build in 2027; and the February 2026 appointment of a Senior Vice President, Market Access and Value, who previously worked on market access for Zolgensma at AveXis. The company describes TSHA-102 as a one-time intrathecal administration with potential to be performed in an outpatient setting, and cites the commercial launch and uptake of trofinetide (DAYBUE) as evidence of market demand. In its second quarter 2026 results announcement, Taysha reported completed payer research in which TSHA-102 was viewed as a high-value therapy, and stated that efficacy, safety, and durability are expected to drive coverage and reimbursement, with durable functional benefit as the key value determinant. Its annual report states that the reimbursement structure of other companies' approved gene therapies could affect the anticipated reimbursement structure of its own products.

Summary: eligible population and cost of care for Rett syndrome

Acadia Pharmaceuticals estimates, based on 2024 claims data, that approximately 6,000 people are diagnosed with Rett syndrome in the United States, within a prevalent population of 6,000 to 9,000, and a prevalent population of 9,000 to 12,000 in the European Union. In IQVIA medical and prescription claims from November 1, 2016, to October 31, 2019, the annual prevalence of a Rett syndrome diagnosis was 0.30 to 0.32 per 10,000 enrollees overall and 0.45 to 0.52 per 10,000 among females. A meta-analysis of 10 studies in females, with 9.57 million women and 673 cases, estimated a pooled prevalence of 7.1 per 100,000 females (95% CI: 4.8, 10.5).

In the same IQVIA claims analysis, 5,940 female patients (3,078 pediatric, 2,862 adult; mean observation period 2.04 years) had mean all-cause healthcare costs of $40,326 per patient per year in 2021 US dollars, comprising $34,772 (86%) in pre-adjudicated medical costs and $5,554 (14%) in adjudicated pharmacy costs. Rett syndrome-related costs comprised 45% of all-cause costs ($14,643 medical and $3,428 pharmacy per patient per year). The largest medical cost components were home or hospice care visits ($12,054), therapeutic services ($7,071), outpatient visits ($6,791), and inpatient visits ($6,088). Mean all-cause costs were $45,718 in pediatric and $34,548 in adult patients. The authors state that pre-adjudicated claims may overestimate costs and that institutional claims are captured less completely than outpatient claims. A related claims analysis estimated mean medical costs of managing gastrointestinal manifestations at $4473 per patient per year ($5530 pediatric, $3341 adult). In the Australian Rett Syndrome Database, mean healthcare costs were AUD 21,158 per patient per year (USD 25,691 as of December 2022), ranging from AUD 238 to AUD 85,776.

In a UK caregiver study, average weekly caregiving time was 98.9 hours, 14% of caregivers worked full time, and 60% had stopped working completely. Genetic testing for MECP2 is listed under procedure codes 81302 (full sequence analysis), 81303 (known familial variant), and 81304 (duplication or deletion variants), and one payer policy states that it may be considered medically necessary to establish a genetic diagnosis when a definitive diagnosis cannot be made without genetic testing. A systematic literature review identified 11 publications reporting cost or healthcare resource use outcomes and stated that cost data in the literature were limited.

Summary: trofinetide as the comparator benchmark

Acadia stated a list price for trofinetide (DAYBUE) of $21.10 per mL, or an estimated average net realized cost to payers of about $375,000 per year. Acadia reported net product sales of DAYBUE of $177.2 million in 2023, $348.4 million in 2024, and $391.4 million in 2025, attributing the 2025 increase to growth in unit sales and a higher average net selling price. In a real-world analysis, 766 of 2,950 eligible individuals (26.0%) initiated trofinetide during the early post-approval period.

Canada's Drug Agency (CDA-AMC) appraised the sponsor's cost-effectiveness and budget impact analyses for trofinetide, and no other published cost-effectiveness or budget impact analysis of a Rett syndrome therapy was identified; amounts below are those reported in that review. The sponsor's Markov cost-utility model compared trofinetide plus best supportive care with best supportive care alone, using 4 health states defined by Rett Syndrome Behaviour Questionnaire (RSBQ) score plus death, a lifetime horizon of 79.1 years, and a 1.5% annual discount rate. Modeled annual drug cost was $455,251 to $1,113,127 (up to 40 kg). Health state utilities ranged from 0.6409 (mild to moderate) to 0.2160 (very severe). The model produced an incremental cost-effectiveness ratio of $5,864,321 per quality-adjusted life-year (QALY) gained (incremental costs $3,386,675; incremental QALYs 0.578), with a 0% probability of cost-effectiveness at $50,000 and $100,000 per QALY gained; a price reduction of more than 98% would be required to meet the $100,000 threshold. Of the incremental QALYs, 93% accrued beyond the trial observation period.

The sponsor's budget impact analysis took the perspective of the pan-Canadian drug plans over 2025 to 2027 and assumed 95, 21, and 22 patients would start publicly reimbursed trofinetide in years 1, 2, and 3. The CDA-AMC reanalysis estimated a 3-year incremental budgetary cost of $166,461,725 (year 1: $53,775,386; year 2: $53,706,466; year 3: $58,979,873), with scenario analyses reaching up to $333 million. CDA-AMC cites approximately 600 to 900 patients with Rett syndrome in Canada. CDA-AMC recommended that trofinetide not be reimbursed by public drug plans.